Recommendations on the Use of ¹⁸F-FDG PET in Oncology

¹ Indiana University School of Medicine, Indianapolis, Indiana
² H. Lee Moffitt Cancer Center at University of South Florida, Tampa, Florida
³ Washington University School of Medicine, St. Louis, Missouri
⁴ Mayo Clinic, Rochester, Minnesota
⁵ Duke University Medical Center, Durham, North Carolina
⁶ Johns Hopkins Medical Center, Baltimore, Maryland
⁷ US Oncology, Newport News, Virginia
⁸ Queen Mary's School of Medicine and Dentistry, London, United Kingdom
⁹ Brigham and Women's Hospital, Boston, Massachusetts
¹⁰ Blue Cross and Blue Shield Association, Washington, DC
¹¹ Vanderbilt University Medical Center, Nashville, Tennessee
¹² National Coalition for Cancer Survivorship, Washington, DC
¹³ Karmanos Cancer Institute, Detroit, Michigan

^* To whom correspondence should be addressed. E-mail: wfletch{at}iupui.edu.

	Abstract

The rationale was to develop recommendations on the use of ¹⁸F-FDG PET in breast, colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma, melanoma, and sarcoma; and unknown primary tumor. Outcomes of interest included the use of ¹⁸F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer. Methods: A search was performed to identify all published randomized controlled trials and systematic reviews in the literature. An additional search was performed to identify relevant unpublished systematic reviews. These publications comprised both retrospective and prospective studies of varied methodologic quality. The anticipated consequences of false-positive and false-negative tests when evaluating clinical usefulness, and the impact of ¹⁸F-FDG PET on the management of cancer patients, were also reviewed. Results and Conclusion: ¹⁸F-FDG PET should be used as an imaging tool additional to conventional radiologic methods such as CT or MRI; any positive finding that could lead to a clinically significant change in patient management should be confirmed by subsequent histopathologic examination because of the risk of false-positive results. ¹⁸F-FDG PET should be used in the appropriate clinical setting for the diagnosis of head and neck, lung, or pancreatic cancer and for unknown primary tumor. PET is also indicated for staging of breast, colon, esophageal, head and neck, and lung cancer and of lymphoma and melanoma. In addition, ¹⁸F-FDG PET should be used to detect recurrence of breast, colorectal, head and neck, or thyroid cancer and of lymphoma.

Key Words: oncology, PET, ¹⁸F-FDG PET

This article has been cited by other articles:

				A. K. Buck, K. Herrmann, T. Stargardt, T. Dechow, B. J. Krause, and J. Schreyogg Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches J. Nucl. Med. Technol., March 1, 2010; 38(1): 6 - 17. [Abstract] [Full Text] [PDF]

				A. K. Buck, K. Herrmann, T. Stargardt, T. Dechow, B. J. Krause, and J. Schreyogg Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches J. Nucl. Med., March 1, 2010; 51(3): 401 - 412. [Abstract] [Full Text] [PDF]

				E. G.C. Troost, D. A.X. Schinagl, J. Bussink, O. C. Boerman, A. J. van der Kogel, W. J.G. Oyen, and J. H.A.M. Kaanders Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET J. Nucl. Med., January 1, 2010; 51(1): 66 - 76. [Abstract] [Full Text] [PDF]

				J. P. Gambini, M. Nunez, P. Cabral, M. Lafferranderie, J. Noble, E. Corchs, R. D'Albora, E. Savio, L. Delgado, and O. Alonso Evaluation of Patients with Head and Neck Cancer by Means of 99mTc-Glucarate J. Nucl. Med. Technol., December 1, 2009; 37(4): 229 - 232. [Abstract] [Full Text] [PDF]

				U. Petrausch, P. Samaras, P. Veit-Haibach, A. Tschopp, J. D. Soyka, A. Knuth, T. F. Hany, A. Mischo, C. Renner, and N. G. Schaefer Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann. Onc., November 13, 2009; (2009) mdp519v1. [Abstract] [Full Text] [PDF]

				B. Glimelius, M. Lahn, S. Gawande, A. Cleverly, C. Darstein, L. Musib, Y. Liu, K. L. Spindler, J.-E. Frodin, A. Berglund, et al. A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer Ann. Onc., November 9, 2009; (2009) mdp521v1. [Abstract] [Full Text] [PDF]

				E. C. Ford, J. Herman, E. Yorke, and R. L. Wahl 18F-FDG PET/CT for Image-Guided and Intensity-Modulated Radiotherapy J. Nucl. Med., October 1, 2009; 50(10): 1655 - 1665. [Abstract] [Full Text] [PDF]

				W. J. McBride, R. M. Sharkey, H. Karacay, C. A. D'Souza, E. A. Rossi, P. Laverman, C.-H. Chang, O. C. Boerman, and D. M. Goldenberg A Novel Method of 18F Radiolabeling for PET J. Nucl. Med., June 1, 2009; 50(6): 991 - 998. [Abstract] [Full Text] [PDF]

				B. J. Krause, K. Herrmann, H. Wieder, and C. M. zum Buschenfelde 18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 89S - 96S. [Abstract] [Full Text] [PDF]

				R. Boellaard Standards for PET Image Acquisition and Quantitative Data Analysis J. Nucl. Med., May 1, 2009; 50(Suppl_1): 11S - 20S. [Abstract] [Full Text] [PDF]

				B. Huang, M. W.-M. Law, and P.-L. Khong Whole-Body PET/CT Scanning: Estimation of Radiation Dose and Cancer Risk Radiology, April 1, 2009; 251(1): 166 - 174. [Abstract] [Full Text] [PDF]

				H. W.M. VAN LAARHOVEN, M. VINKEN, R. MUS, U. FLUCKE, W. J.G. OYEN, and W. T. VAN DER GRAAF The Diagnostic Hurdle of an Elderly Male with Bone Pain: How 18F-FDG-PET Led to Diagnosis of a Leiomyosarcoma of the Adrenal Gland Anticancer Res, February 1, 2009; 29(2): 469 - 472. [Abstract] [Full Text] [PDF]

				M. Morikawa, Y. Demura, T. Ishizaki, S. Ameshima, I. Miyamori, M. Sasaki, T. Tsuchida, H. Kimura, Y. Fujibayashi, and H. Okazawa The Effectiveness of 18F-FDG PET/CT Combined with STIR MRI for Diagnosing Nodal Involvement in the Thorax J. Nucl. Med., January 1, 2009; 50(1): 81 - 87. [Abstract] [Full Text] [PDF]

				K.-Y. Chang, J.-Y. Chang, J. Chao, and Y. Yen Modern Staging and Utility of PET Imaging in Esophageal Cancer Management J Natl Compr Canc Netw, October 1, 2008; 6(9): 862 - 869. [Abstract] [PDF]

				N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF]